Amyotrophic lateral sclerosis / نيكوتين

Aminoadamantane derivatives as therapeutic agents

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Aminoadamantane derivatives as therapeutic agents

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

BACKGROUND OF THE INVENTION Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et

Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

PRIORITY TO RELATED APPLICATIONS This application claims the benefit of European Application No. 04106665.5, filed Dec. 17, 2004, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION .gamma.-Aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter,

Phenyl-substituted nicotinic ligands, and methods of use thereof

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

Phenyl-substituted nicotinic ligands, and methods of use thereof

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

Urea compounds and their use as enzyme inhibitors

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Urea compounds and their use as enzyme inhibitors

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

Triazinedione derivatives as GABA.sub.B receptor modulators

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

SUMMARY OF THE INVENTION ##STR00002## The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B

Triazinedione derivatives as GABA.sub.B receptor modulators

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

SUMMARY OF THE INVENTION ##STR00002## The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B

6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I ##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA

6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I ##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA

Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

The invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo-[3,2-]quinoxaline derivatives of the formula I ##STR00002## in which A-B-D is --NR.sup.6--CR.sup.2.dbd.N--, --N.dbd.CR.sup.2--NR.sup.6-- or --N.dbd.CR.sup.7--CR.sup.8.dbd.N--, R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl,

Cytokine antagonists for neurological and neuropsychiatric disorders

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

FIELD OF THE INVENTION The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic

Cytokine antagonists for neurological and neuropsychiatric disorders

يمكن للمستخدمين المسجلين فقط ترجمة المقالات

الدخول التسجيل فى الموقع

FIELD OF THE INVENTION The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic

amyotrophic lateral sclerosis/نيكوتين

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

Aminoadamantane derivatives as therapeutic agents

Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors

Phenyl-substituted nicotinic ligands, and methods of use thereof

Phenyl-substituted nicotinic ligands, and methods of use thereof

Urea compounds and their use as enzyme inhibitors

Urea compounds and their use as enzyme inhibitors

Triazinedione derivatives as GABA.sub.B receptor modulators

Triazinedione derivatives as GABA.sub.B receptor modulators

6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

Cytokine antagonists for neurological and neuropsychiatric disorders

Cytokine antagonists for neurological and neuropsychiatric disorders

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم